Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Other Non-Current Assets (2021 - 2025)

ARS Pharmaceuticals (SPRY) has disclosed Other Non-Current Assets for 5 consecutive years, with $2.8 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Assets fell 10.53% to $2.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.8 million through Dec 2025, down 10.53% year-over-year, with the annual reading at $2.8 million for FY2025, 10.53% down from the prior year.
  • Other Non-Current Assets hit $2.8 million in Q4 2025 for ARS Pharmaceuticals, down from $2.9 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $3.1 million in Q1 2025 to a low of $21000.0 in Q1 2023.
  • Historically, Other Non-Current Assets has averaged $1.5 million across 5 years, with a median of $664000.0 in 2023.
  • Biggest five-year swings in Other Non-Current Assets: soared 585.71% in 2022 and later plummeted 91.6% in 2023.
  • Year by year, Other Non-Current Assets stood at $350000.0 in 2021, then soared by 740.0% to $2.9 million in 2022, then crashed by 78.3% to $638000.0 in 2023, then surged by 388.09% to $3.1 million in 2024, then decreased by 10.53% to $2.8 million in 2025.
  • Business Quant data shows Other Non-Current Assets for SPRY at $2.8 million in Q4 2025, $2.9 million in Q3 2025, and $3.1 million in Q2 2025.